GlaxoSmithKline Reveals Ingenuity
In a further validation of Big Pharma�s acceptance of systems biology, GlaxoSmithKline has licensed part of the Ingenuity Pathways Knowledge Base to facilitate genome-wide computational analysis of biological systems underlying disease.